Oral Abstract Schedule

Thursday Oral Abstract Schedule

1:30 - 2:00 pmDr. Laura SelmicSOTA PRESENTATION
Intraoperative optical coherence tomography
for soft tissue sarcoma surgical margin assessment
2:00 - 2:12 pmDr. Paul AveryFeline lymphocytosis: Immunophenotypic
characterization and clinical outcome

2:12 - 2:24 pmDr. Brittany FowlerEcological-level analysis of canine and feline primary
lung tumors and environmental radon levels
2:24 - 2:36 pmDr. Changseok KimDiagnostic efficiency of ultrasound-guided aspiration
of medial retropharyngeal lymph node in dogs

2:36 - 2:48 pmDr. Renata SettiImmunocytochemistry in liquid-based cytology:
A new approach to immunophenotyping canine lymphoma

2:48 - 3:00 pmDr. Maria DagliIntratumoral administration of a dual UPA and
MMP-activated engineered anthrax toxin for
treatment of canine oral melanoma: Pilot study
3:00 - 3:30 pmDiscussion
3:30 - 5:00 pmAfternoon Break and Poster Presentation Session


Friday Oral Abstract Schedule

8:00 - 9:00 AMDr. Christopher CorlessKEYNOTE PRESENTATION:
New approaches to the molecular classification
of cancers
9:00 - 9:30 AMDr. Doug ThammSOTA PRESENTATION:
TANOVEA-CA1 (rabacfosadine for injection) in canine
lymphoma: History, development and
collaborative studies
9:30 - 9:42 amDr. Matthew BerryInvestigating the differential expressions of PSMA in
canine uroepithelial carcinomas and its potential to aid
disease-based stratification for the rational institution
of conventional chemotherapeutic agents
9:42 - 9:54 amDr. Jenna BurtonPhase I evaluation of doxorubicin-loaded micelles
in dogs with non-hodgkin lymphoma
9:54 - 10:06 amDr. Shawna KlahnPhase I clinical trial of oxaliplatin in canine cancer patients
10:06 - 10:36 amMorning Break
10:36 - 11:06 amDr. Erin DickersonSOTA PRESENTATION:
Adrenergic receptor antagonists alter the
intracellular accumulation of doxorubicin and
sensitize canine hemangiosarcoma cells
to chemotherapy
11:06 - 11:18 amDr. Andrea DedeauxCCNU-induced hepatotoxicity in healthy dogs
11:18 - 11:30 amDr. Renee Laufer-AmorimPiroxicam enhances the antiproliferative effect of BMI1
inhibition in canine mammary gland and melanoma cell lines

11:30 - 12:00 pmDiscussion
1:30 - 2:30 pmSusan HedlundKEYNOTE PRESENTATION:
When the well runs dry:
Compassion fatigue, burnout and resilience in practice
2:30 - 3:00 pmDr. Michelle TurekSOTA PRESENTATION:
Radiotherapy delivery systems: When is more(advanced) better?
3:00 - 3:30 pmAfternoon Break
3:30 - 3:42 pmDr. Kenji HosoyaA dose-intense combination chemotherapy followed by
marrow-sparing half-body irradiation (HU-MSHBI) in dogs with
multicentric lymphoma: A prospective pilot study

3:42 - 3:54 pmDr. Michelle LaRueTreatment of canine apocrine gland anal sac
adenocarcinoma with radiation therapy: 71 cases
3:54 - 4:06 pmDr. Melanie MooreAssessment of tolerance for electronic
plesiotherapy and brachytherapy for dogs
with naturally occurring tumors
4:06 - 4:18 pmDr. Valerie PoirierClinical-dosimetric relationship between lacrimal gland
dose and the development of keratoconjunctivitis
dicca (KCS) following treatment of canine nasal tumours
with intensity-modulated radiation therapy (IMRT)
4:18 - 4:30 pmDr. Leanne MagestroComparison of various imaging modalities for setup
verification prior to delivery of stereotactic radiation
therapy for head and neck cancers in veterinary patients

4:30 - 5:00 pmDiscussion


Saturday Oral Abstract Schedule

8:00 - 9:00 AMDr. Daniel PromislowKEYNOTE PRESENTATION:
The Dog Aging Project:
An open science resource for cancer research
9:00 - 9:30 AMDr. Hans KlingemannSOTA PRESENTATION:
Cancer immunotherapy for dogs:
Running behind humans
9:30 - 9:42 amDr. Jimmy TranSpecific HDAC3 inhibition increases MHC class II
gene expression in canine B-cell lymphoma
9:42 - 9:54 amDr. Jennifer LenzGeneration of myeloid derived suppressor
cells by tumor exosomes
9:54 - 10:25 amMorning Break
10:25 - 10:55 amDr. Xuan PanSOTA PRESENTATION:
Targeting MAPK and JAK2-STAT3 pathways
in canine diffuse large B-cell lymphomas
10:55 - 11:07 AMDr. Kyle RenaldoValidation of protein arginine methyltransferase
5 (PRMT5) as a candidate therapeutic target in the
canine model of non-hodgkin lymphoma
11:07 - 11:19 amDr. Alycen LundbergTargeted therapy for feline pulmonary carcinoma
through exploitation of preferential NQO1 expressions
and the drug isobutyl-deoxynyboquinone (IB-DNQ)
11:19 - 11:31 amDr. Paul RossmanPhase I clinical trial of vemurafenib in dogs with
urinary tract transitional cell carcinoma (TCC) harboring
the BRAF V600E mutation
11:31 - 12:00 pmDiscussion
1:30 - 1:42 pmDr. Haley LeeperT Lymphocyte population patterns in canine osteosarcoma
patients on cytotoxic chemotherapy
1:42 - 1:54 pmDr. Julia LabadieChronic inflammation and T zone lymphoma:
A case-control study of aged golden retrievers
1:54 - 2:06 pmDr. Derek KorpelaAdrenergic receptor antagonists limit metabolic plasticity
and reduce viability of canine hemangiosarcoma cells
2:06 - 2:18 pmDr. Steven MoiranoAssociation of prognostic features and treatment on survival
time of dogs with systemic mastocytosis
2:18 - 2:30 pmDr. Susanne GamperlEffects of histamine receptor blockers on growth and
IgE-dependent histamine release of canine
neoplastic mast cells
2:30 - 2:42 pmDr. Shay BrachaLiquid biopsy of circulating exosomes is a strong predictor
for presence of disease and stage in dogs with osteosarcoma
2:42 - 2:54 pmDr. Chad JohannesEvaluation of factors associated with survival in dogs
with lymphoma treated with prednisone. The Canine
Lymphoma Steroid Only (CALYPSO) open-label
prospective clinical trial: 69 cases (2016-2017)

2:54 - 3:30 pmAfternoon Break